Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 44,259 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 44,259 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $6.99, for a total value of $309,370.41. Following the completion of the transaction, the insider owned 4,231,434 shares of the company’s stock, valued at $29,577,723.66. This trade represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total value of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total value of $280,238.40.

Entrada Therapeutics Stock Up 0.7%

Shares of TRDA stock traded up $0.05 during mid-day trading on Monday, hitting $7.05. 450,412 shares of the company’s stock were exchanged, compared to its average volume of 325,154. The stock has a market cap of $274.51 million, a price-to-earnings ratio of -1.78 and a beta of -0.26. Entrada Therapeutics, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $16.45. The stock has a 50-day simple moving average of $7.08 and a two-hundred day simple moving average of $9.31.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The business had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.32 million. As a group, analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP boosted its position in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after purchasing an additional 206,911 shares during the period. 5AM Venture Management LLC bought a new stake in Entrada Therapeutics in the second quarter worth about $29,854,949. GSA Capital Partners LLP bought a new stake in Entrada Therapeutics in the second quarter worth about $648,000. Nantahala Capital Management LLC acquired a new stake in Entrada Therapeutics in the 2nd quarter valued at about $2,212,232. Finally, ADAR1 Capital Management LLC acquired a new stake in Entrada Therapeutics in the 2nd quarter valued at about $114,000. 86.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TRDA has been the topic of several recent analyst reports. Guggenheim cut their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Finally, Roth Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Entrada Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.75.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.